Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Atrium Health

Neither a doctor nor a teaching hospital

Research payments

$2,080,302

103 payments

Through program year 2025, Atrium Health is reported as receiving $2,080,302 in research payments, across 103 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $180,096 21
2024 Research $431,946 32
2023 Research $561,643 21
2022 Research $289,435 12
2021 Research $76,297 10
2020 Research $155,913 2
2019 Research $384,972 5

Breakdown

Who paid Research payments · program years 2019–2025
  1. Y-mAbs Therapeutics, Inc. $542,989 2 payments
  2. Takeda Pharmaceuticals U.S.A., Inc. $537,558 11 payments
  3. Amgen Inc. $531,248 5 payments
  4. Novartis Pharmaceuticals Corporation $164,133 8 payments
  5. Impulse Dynamics (USA) Inc. $74,691 38 payments
  6. Marinus Pharmaceuticals, Inc. $72,862 16 payments
  7. Bayer HealthCare Pharmaceuticals Inc. $67,118 7 payments
  8. Exelixis Inc. $35,082 6 payments
  9. Genentech, Inc. $17,000 1 payment
  10. Aziyo Biologics, Inc. $12,190 2 payments
Studies the money was for Research payments · program years 2019–2025
  1. Aggressive Smoldering Curative Approach Evaluating Novel Therapies and Transplant (ASCENT): A Phase 2 Trial of Induction, Consolidation, and Maintenance in Patients with High Risk Smoldering Multiple Myeloma (A Black Swan Research Initiative cure bas $527,290 2 payments
  2. A Phase 1/2 Open-Label Study to Investigate the Safety and Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of Tak-573 As A Single Agent in Patients With Refractory Multiple Myeloma $487,058 8 payments
  3. Naxitamab Added to Induction for Newly Diagnosed High-Risk Neuroblastoma $323,834 1 payment
  4. Naxitamab Added to Induction for Newly Diagnosed High-Risk Neuroblastoma $219,155 1 payment
  5. A phase 2, randomized, double-blind, placebo-controlled parallel group study of VHB937 in Amyotrophic Lateral Sclerosis (ALS) over 40 weeks followed by an Open-label Extension (ASTRALS) $80,219 2 payments
  6. Post Approval Study (PAS) of the OPTIMIZER Smart and CCM Therapy $63,397 31 payments
  7. VictORION-INCLUSION: Evaluating INClisiran as a soLUtion to Improve LDL-C Management and cloSe Care Gaps in an Inclusive ASCVD and ASCVD Risk Equivalent populatiON $52,195 1 payment
  8. A Phase 1/2 Study of the Safety, Pharmacokinetics, and Anti-Tumor Activity of the Oral Egfr/Her2 Inhibitor Tak-788 (Ap32788) in Non-Small Cell Lung Cancer $49,448 2 payments
  9. A multicenter non-randomized open-label phase 1b study to determine the maximum tolerated and recommended phase 2 dose of the ATR Inhibitor BAY 1895344 in combination with pembrolizumab and to characterize its safety tolerability pharmacokinetics and preliminary anti-tumor activity in patients with advanced solid tumors $48,086 5 payments
  10. A Randomized Open-Label Phase 3 Study of XL092 + Atezolizumab vs Regorafenib in Subjects with Metastatic Colorectal Cancer $35,082 6 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record